Download PDF
J Pediatr Intensive Care 2020; 09(01): 021-026
DOI: 10.1055/s-0039-1695061
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Invasive Candida Infections in a Pediatric Intensive Care Unit in Turkey: Evaluation of an 11-Year Period

Nagehan Aslan
1   Department of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Dincer Yildizdas
1   Department of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Derya Alabaz
2   Department of Pediatric Infectious Disease, Cukurova University Faculty of Medicine, Adana, Turkey
,
Ozden Ozgur Horoz
1   Department of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Ahmet Yontem
1   Department of Pediatric Intensive Care, Cukurova University Faculty of Medicine, Adana, Turkey
,
Emine Kocabas
2   Department of Pediatric Infectious Disease, Cukurova University Faculty of Medicine, Adana, Turkey
› Author Affiliations
Further Information

Publication History

19 May 2019

13 July 2019

Publication Date:
06 September 2019 (online)

Also available at
    Permissions and Reprints

Abstract

The aim of this study was to evaluate the Candida species, predisposing factors, antifungal treatment approaches, and clinical outcomes of invasive Candida infections (ICIs) in a tertiary pediatric intensive care unit (PICU). A retrospective study was performed from January 2008 to January 2019 including 102 children with ICIs who were admitted to a university hospital in southeastern Turkey. Positive blood cultures were detected in 43 (42.1%) patients, and positive urine cultures were detected in 59 (57.8%). According to our results, Candida albicans (42.2%) was the most common species for all isolates followed by C. parapsilosis (17.6%). In our patient population, non-albicans Candida species were dominant (57.8%) in all isolates. The most common facilitating factor in our study was the use of mechanical ventilator support (87.3%). The mortality rate of our patients with ICIs was 13.7%. Candida albicans was found to have the highest mortality rate among all Candida species (30.7%). When we compared patients with C. albicans and those with non-albicans Candida species in terms of risk factors, we detected a significant difference between the two groups for total parenteral nutrition use (p = 0.027). Fluconazole was the most preferred (58.8%) treatment option in our PICU for ICIs. Our results showed an increased trend in micafungin use in recent years. ICIs are a significant problem due to the high mortality and morbidity rates in critically ill pediatric patients in PICUs. In recent years, an increase in Candida infections caused by non-albicans Candida species has been reported. Multicenter prospective studies are needed to determine the risk factors for ICIs.

Keywords

pediatric - invasive candidiasis - non-albicans Candida - pediatric intensive care unit
 

  • References

  • 1 Pappas PG, Kauffman CA, Andes D. , et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48 (05) 503-535
    CrossrefPubMedGoogle Scholar
  • 2 Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20 (01) 133-163
    CrossrefPubMedGoogle Scholar
  • 3 Zaoutis T. Candidemia in children. Curr Med Res Opin 2010; 26 (07) 1761-1768
    CrossrefPubMedGoogle Scholar
  • 4 Mesini A, Bandettini R, Caviglia I. , et al. Candida infections in paediatrics: results from a prospective single-centre study in a tertiary care children's hospital. Mycoses 2017; 60 (02) 118-123
    CrossrefPubMedGoogle Scholar
  • 5 Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence 2014; 5 (01) 161-169
    CrossrefPubMedGoogle Scholar
  • 6 Orasch C, Mertz D, Garbino J. , et al; Fungal Infection Network of Switzerland (FUNGINOS). Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. J Infect 2018; 76 (05) 489-495
    CrossrefPubMedGoogle Scholar
  • 7 Harrington R, Kindermann SL, Hou Q, Taylor RJ, Azie N, Horn DL. Candidemia and invasive candidiasis among hospitalized neonates and pediatric patients. Curr Med Res Opin 2017; 33 (10) 1803-1812
    CrossrefPubMedGoogle Scholar
  • 8 Montagna MT, Lovero G, Borghi E. , et al. Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci 2014; 18 (05) 661-674
    PubMedGoogle Scholar
  • 9 Tragiannidis A, Fegeler W, Rellensmann G. , et al. Candidaemia in a European paediatric university hospital: a 10-year observational study. Clin Microbiol Infect 2012; 18 (02) E27-E30
    CrossrefPubMedGoogle Scholar
  • 10 Guery BP, Arendrup MC, Auzinger G. , et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis. Intensive Care Med 2009; 35 (01) 55-62
    CrossrefPubMedGoogle Scholar
  • 11 Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36 (05) 309-332
    CrossrefPubMedGoogle Scholar
  • 12 Pfaller MA, Messer SA, Hollis RJ. , et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol 2009; 47 (10) 3185-3190
    CrossrefPubMedGoogle Scholar
  • 13 Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus . J Clin Microbiol 2004; 42 (10) 4419-4431
    CrossrefPubMedGoogle Scholar
  • 14 Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167 (05) 695-701
    CrossrefPubMedGoogle Scholar
  • 15 Pagano L, Caira M, Candoni A. , et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91 (08) 1068-1075
    PubMedGoogle Scholar
  • 16 Profumo RJ. Pediatric liver transplant recipients: mortality analysis over 20 years. J Insur Med 2006; 38 (01) 3-8
    PubMedGoogle Scholar
  • 17 Almooosa Z, Ahmed GY, Omran A. , et al. Invasive candidiasis in pediatric patients at King Fahad Medical City in Central Saudi Arabia. A 5-year retrospective study. Saudi Med J 2017; 38 (11) 1118-1124
    CrossrefPubMedGoogle Scholar
  • 18 Palazzi DL, Arrieta A, Castagnola E. , et al. Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study. Pediatr Infect Dis J 2014; 33 (12) 1294-1296
    CrossrefPubMedGoogle Scholar
  • 19 Dutta A, Palazzi DL. Candida non-albicans versus Candida albicans fungemia in the non-neonatal pediatric population. Pediatr Infect Dis J 2011; 30 (08) 664-668
    CrossrefPubMedGoogle Scholar
  • 20 Omrani AS, Makkawy EA, Baig K. , et al. Ten-year review of invasive Candida infections in a tertiary care center in Saudi Arabia. Saudi Med J 2014; 35 (08) 821-826
    PubMedGoogle Scholar
  • 21 Sütçü M, Acar M, Genç GE. , et al. Evaluation of Candida species and antifungal susceptibilities among children with invasive candidiasis. Turk Pediatri Ars 2017; 52 (03) 145-153
    CrossrefPubMedGoogle Scholar
  • 22 Noni M, Stathi A, Vaki I, Velegraki A, Zachariadou L, Michos A. Changing epidemiology of invasive candidiasis in children during a 10-year period. J Fungi (Basel) 2019; 5 (01) 19
    PubMedGoogle Scholar
  • 23 Celebi S, Hacimustafaoglu M, Ozdemir O, Ozkaya G. Nosocomial candidaemia in children: results of a 9-year study. Mycoses 2008; 51 (03) 248-257
    CrossrefPubMedGoogle Scholar
  • 24 Devrim İ, Demirağ B, Yaman Y. , et al. A 7-year study of the distribution of nosocomial candidemia in children with cancer. Turk J Pediatr 2015; 57 (03) 225-229
    PubMedGoogle Scholar
  • 25 Öncü B, Belet N, Emecen AN, Birinci A. Health care-associated invasive Candida infections in children. Med Mycol 2019 (e-pub ahead of print). doi: 10.1093/mmy/myz005
    PubMedGoogle Scholar
  • 26 Sievert DM, Ricks P, Edwards JR. , et al; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34 (01) 1-14
    PubMedGoogle Scholar
  • 27 Benjamin Jr DK, Stoll BJ, Gantz MG. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010; 126 (04) e865-e873
    CrossrefPubMedGoogle Scholar
  • 28 Acar A, Oncül O, Küçükardali Y, Ozyurt M, Haznedaroğlu T, Cavuşlu S. Yoğun bakim ünitelerinde saptanan Candida enfeksiyonlarinin epidemiyolojik özellikleri ve mortaliteye etki eden risk faktörleri. Mikrobiyol Bul 2008; 42 (03) 451-461
    PubMedGoogle Scholar
  • 29 Çekin Y, Pekintürk N, Çekin AH. Evaluation of species distribution and antifungal resistance of Candida isolates from hospitalized patients. J Clin Anal Med 2015; 6: 8-11
    PubMedGoogle Scholar
  • 30 Hazırolan G, Yıldıran D, Baran I, Mumcuoğlu İ, Aksu N. Yatan hasta örneklerinden izole edilen Candida izolatlarının tür dağılımlarının ve antifungal duyarlılık profillerinin değerlendirilmesi. Turk Hij Deney Biyol Derg 2015; 72: 17-26
    PubMedGoogle Scholar
  • 31 Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20 (03) 571-575
    CrossrefPubMedGoogle Scholar
  • 32 Filioti J, Spiroglou K, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med 2007; 33 (07) 1272-1283
    CrossrefPubMedGoogle Scholar
  • 33 Conde-Rosa A, Amador R, Pérez-Torres D. , et al. Candidemia distribution, associated risk factors, and attributed mortality at a university-based medical center. P R Health Sci J 2010; 29 (01) 26-29
    PubMedGoogle Scholar
  • 34 Blyth CC, Chen SC, Slavin MA. , et al; Australian Candidemia Study. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009; 123 (05) 1360-1368
    CrossrefPubMedGoogle Scholar
  • 35 Pappas PG, Kauffman CA, Andes DR. , et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62: 1-50
    CrossrefPubMedGoogle Scholar
  • 36 Hope WW, Castagnola E, Groll AH. , et al; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012; 18 (Suppl. 07) 38-52
    CrossrefPubMedGoogle Scholar